Clinical Trials Logo

Neurotoxic Disorders clinical trials

View clinical trials related to Neurotoxic Disorders.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00727922 Completed - Cancer Clinical Trials

Protective Effect of Mangafodipir Against Oxaliplatin Neurotoxicity

MnDPDP-K04
Start date: June 2008
Phase: Phase 2
Study type: Interventional

Oxaliplatin is a major antitumor agent but its use is limited by potentially disabling neurotoxicity, characterized by a sensitive defect in the extremities.Mangafodipir is a MRI contrast agent with antioxidant properties. Our previous laboratory works showed that mangafodipir is able to prevent hematologic toxicity of several chemotherapy agents, including oxaliplatin and to increase their antitumor activity. Preliminary clinical data suggested that mangafodipir could prevent oxaliplatin neurotoxicity.The primary purpose of the present study is to assess the protective effect of mangafodipir in patients who have a already moderate oxaliplatin neuropathy and in whom the continuation of this treatment is desirable because of significant antitumor effect.